Home/Filings/4/0001415889-22-006631
4//SEC Filing

Shearman Mark S 4

Accession 0001415889-22-006631

CIK 0001650664other

Filed

Jun 15, 8:00 PM ET

Accepted

Jun 16, 4:15 PM ET

Size

4.9 KB

Accession

0001415889-22-006631

Insider Transaction Report

Form 4
Period: 2022-06-15
Shearman Mark S
EVP, Chief Scientific Officer
Transactions
  • Sale

    Common Stock

    2022-06-15$10.06/sh5,145$51,74568,349 total
Footnotes (1)
  • [F1]Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 19, 2021 and represents the sale of shares necessary to meet tax withholding obligations as a result of vesting in restricted stock units and in performance stock units on June 14, 2022. The sale does not represent a discretionary trade by the Reporting Person.

Issuer

Editas Medicine, Inc.

CIK 0001650664

Entity typeother

Related Parties

1
  • filerCIK 0001643799

Filing Metadata

Form type
4
Filed
Jun 15, 8:00 PM ET
Accepted
Jun 16, 4:15 PM ET
Size
4.9 KB